Publication
Pensions Regulator announces changes to the DC scheme return for 2024
The Regulator has issued an online announcement about upcoming changes to its DC scheme return.
Global | Publication | January 2019
The convergence of technology and life sciences was a defining feature of 2018. The boundaries of what defines the life sciences sector have increasingly blurred as life sciences companies look to the value of data in the search for innovation.
This does not mean, however, that “traditional” life sciences transactions are not going ahead. Some of the largest global deals have involved the acquisition of “traditional” research and development assets.
Case study
Norton Rose Fulbright advised on the sale of Acumyn Inc., a healthcare technology company, to a global Swedish health technology company, Elekta. This included negotiating Acumyn’s joint development and marketing agreement with Elekta, as well as acting on a number of complex mandates related to Acumyn’s technology and licensing with University Health Network, a leading Toronto based hospital network.
Publication
The Regulator has issued an online announcement about upcoming changes to its DC scheme return.
Publication
On July 30, 2024, the Regulator published its market oversight report on how trustees are complying with their environmental, social and governance (ESG) duties, including in respect of climate change.
Publication
We reported last month that the Court of Appeal had agreed with the High Court’s previous judgment that all rule amendments to contracted-out DB schemes between 1997 and 2013 require written actuarial certification. Three pensions professional bodies have now issued a joint statement on the effect of the ruling.
Subscribe and stay up to date with the latest legal news, information and events . . .
© Norton Rose Fulbright LLP 2023